Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Abcentra 424-369-4401
info@abcentra.com


Study Location:

Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - Focused Orticumab Research for Treating Inflammation in Coronary Arteries

Focused Orticumab Research for Treating Inflammation in Coronary Arteries

Recruiting

Open to: ALL

Age: 18.0 - N/A

Medical Conditions

Acute Coronary Syndromes
Coronary Arterial Disease (CAD)
Inflammation
Heart Disease
Myocardial Infarct
Atherosclerotic Coronary Vascular Disease


This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


The goal of this clinical trial is to determine the clinical effect of orticumab treatment on inflammation in study participants with prior myocardial infarction who have elevated coronary inflammation based on CCTA. The main question it aims to answer is:

Clinical effects of orticumab treatment on inflammation of the coronary artery parameters measured with CCTA

Researchers will compare the effects with placebo group after 6 months of treatment

Participants will Keep the planned study visit appointments Provide complete information about medical and medical history Speak to the study doctor before changing any of non-study treatments, including starting new medications, receiving any vaccinations, or setting out to join any other clinical studies

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Aug 2025 Feb 2027

INTERVENTIONAL

Intervention Type : DRUG
Intervention Description : Orticumab treatment for 24 weeks for post MI population

Intervention Arm Group : Orticumab High Dose;Orticumab Low Dose;

Intervention Type : DRUG
Intervention Description : Placebo for 24 weeks for the post MI population

Intervention Arm Group : Placebo High Dose;Placebo Low Dose;



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • Abcentra Investigational Site
    London
    Greater London
    EC1M 6BQ
  • Abcentra Investigational Site
    Manchester
    Greater Manchester
    M23 9LT
  • Abcentra Investigational Site
    Oxford
    Oxfordshire
    OX3 9DU
  • Abcentra Investigational Site
    Bath
    Somerset
    BA1 3NG
  • Abcentra Investigational Site
    Sheffield
    South Yorkshire
    S57AU


The study is sponsored by Abcentra




We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?

Read full details for Trial ID: NCT06927739
Last updated 24 January 2026

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.